insights_auto
Waarom is DRREDDY gedaald 2,69%?
Meer informatiechevron_right
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
₹ 1.171,40
arrow_downward
-2,69%(-32,40) 1D
8 okt, 13:10:27 GMT+5:30 · INR
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor DRREDDY genereren…
Openen
₹ 1.197,30
Hoog
₹ 1.201,20
Laag
₹ 1.167,20
Beursw.
973,68 mld.
Gem. vol.
1,79 mln.
Volume
1,46 mln.
Dividend
0,68%
Kwartaaldividend
₹ 2,00
Ex-dividenddatum
10 jul 2026
Koers/winst-verhouding
30,29
52 wk hoog
₹ 1.414,90
52 wk laag
₹ 1.101,00
WPA
₹ 38,67
Uitstaande aandelen
166,06 mln.
Aantal medewerkers
28K
Openen
₹ 1.197,30
Hoog
₹ 1.201,20
Laag
₹ 1.167,20
Beursw.
973,68 mld.
Gem. vol.
1,79 mln.
Volume
1,46 mln.
Dividend
0,68%
Kwartaaldividend
₹ 2,00
Ex-dividenddatum
10 jul 2026
Koers/winst-verhouding
30,29
52 wk hoog
₹ 1.414,90
52 wk laag
₹ 1.101,00
WPA
₹ 38,67
Uitstaande aandelen
166,06 mln.
Aantal medewerkers
28K
Nieuwsartikelen
Van webbronnen en nieuwspartners
TipRanks
·
20 uur geleden
Dr. Reddy’s Sets October 23 Date for Q2 FY27 Results and Global Earnings Call
Stock Titan
·
20 uur geleden
A 10 a.m. ET earnings call is scheduled for October 23 at Dr. Reddy’s (RDY).
TipRanks
·
2 dagen geleden
Dr. Reddy’s U.S. Subsidiary Hit with Modest IRS Penalty, Assessed as Non‑Material
Profiel
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Over Dr Reddy's Laboratories Ltd
CEOErez Israeli
Medewerkers27,5K
Opgericht1984
HoofdkantoorHaiderabad, Andhra Pradesh, India
Sector-
Websitedrreddys.com